NCT00689000 - Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromeMultiple Myeloma

Interventions

DRUG

CHR-2797 (tosedostat): Aminopeptidase inhibitor

"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"

Trial Locations (1)

EH25 9PP

Nexus Oncology Ltd, Edinburgh